GE HealthCare Reports Q2 2025 Earnings: Strong Revenue Growth Amid Rising Costs and Tariff Pressures

GE HealthCare Technologies Inc. (NASDAQ: GEHCV) - Q2 2025 Earnings Report

GE HealthCare Technologies Inc. recently released its quarterly earnings report for the period ending June 30, 2025. The company demonstrated solid growth in various segments while also highlighting some challenges related to costs and external economic factors.

Positive Aspects of the Income Statement:

• Total Revenues: Increased to $5.007 billion, a 3% increase compared to $4.839 billion in Q2 2024.
• Net Income: Rose to $500 million, up from $435 million in Q2 2024, reflecting a 15% year-over-year increase.
• Earnings Per Share (EPS): Improved to $1.06 (diluted), compared to $0.93 in the same quarter of the previous year.
• Operating Income: Increased to $654 million, an 8% growth from $608 million in Q2 2024.
• Cash Balance: Grew to $3.763 billion from $2.889 billion at the end of 2024.

Negative Aspects of the Income Statement:

• Cost of Goods Sold: Increased for both products ($2.160 billion) and services ($863 million), impacting gross profit margins.
• Operating Expenses: Total operating expenses amounted to $1.331 billion, slightly down but still significant compared to revenues.
• High Interest Charges: Interest and other financial charges were $113 million, although down from $131 million, they still exert pressure on overall profitability.
• Impact from Tariffs: Increased costs due to ongoing tariffs have pressured margins, particularly in the Imaging and PCS segments.

Key Performance Metrics:

• Gross Profit: Stood at $1.985 billion, slightly down from $2.002 billion in Q2 2024.
• Segment Revenue Growth: Imaging ($2.204 billion), AVS ($1.289 billion), PCS ($778 million), and PDx ($729 million) demonstrated diverse revenue growth across segments.
• Free Cash Flow: Increased to $106 million from $92 million year-over-year.

In conclusion, while GE HealthCare Technologies showed significant revenue growth and improved profitability, challenges related to rising costs and external economic pressures, particularly tariffs, present ongoing concerns. Investors should weigh these factors against the company's strong earnings growth and robust cash position.